The Epilepsy Foundation has announced a transformative partnership with Iaso Ventures, a prominent venture capital firm, to establish the Iaso NeuroImpact Fund. This innovative fund serves as a cornerstone for advancing the development of pioneering therapeutics, diagnostics and technologies aimed at revolutionising the landscape of care for epilepsy and seizure disorders. Leveraging the professional investment acumen of Iaso Ventures and the profound research and clinical expertise of the Epilepsy Foundation, the NeuroImpact Fund is poised to catalyse breakthroughs in epilepsy treatment and support.
The primary objective of the NeuroImpact Fund is to create a sustainable and enduring impact for people affected by epilepsy, as well as their families and caregivers. Building upon a legacy of fostering innovation, the Epilepsy Foundation has been instrumental in advancing new products through initiatives such as the Shark Tank Competition, New Therapy Commercialisation Grants, and the Epilepsy Innovation Institute. Recognising the critical need for bridging the gap between research and commercialisation, the Foundation has identified the establishment of the NeuroImpact Fund as a primary source of funding to help accelerate therapies to stop seizures, find cures and save lives.
“Throughout history, the Epilepsy Foundation has been at the forefront of supporting early-stage companies developing innovative solutions for epilepsy,” said Bernice Martin Lee, Chief Executive Officer, Epilepsy Foundation. “The NeuroImpact Fund represents a significant milestone in our journey, leveraging our collective expertise and resources to continue to drive innovation and improve the lives of people living with epilepsy.”
Click below to share this article